NDA 215025 · Maia Pharms INC
Sodium Phenylacetate and Sodium Benzoate
Sodium Benzoate, Sodium Phenylacetate · Intravenous
Last checked: Nov 20, 2026Latest source record: Jun 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 10, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,672
341 Phase 3, 113 recruiting
FAERS reports
9
7 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 9, 2024.
Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle.
Mechanism: Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection, phenylacetate and benzoate, provide an alternative...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SODIUM PHENYLACETATE AND SODIUM BENZOATE · SODIUM BENZOATE 10%; SODIUM PHENYLACETATE 10% (2GM/20ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Benzoate" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)Pivotal-lookingRecruiting
McMaster UniversityAcademic, hospital or other
NCT05114096 · 3,254 participants (planned) · Start Jul 20, 2023 · Primary completion Dec 31, 2026
Drug: Celestone + placebo; Celestone + Celestone · For: Preterm Birth; Premature Birth; Complication of Prematurity and 2 more
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 25 sites in all
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Simplified Antibiotic Therapy for Sepsis in Young InfantsPivotal-lookingCompleted
Aga Khan UniversityAcademic, hospital or other
NCT01027429 · 2,543 participants · Start Dec 2009 · Primary completion Dec 2013
Drug: procaine penicillin and gentamicin; amoxicillin and gentamicin and 1 more · For: Neonatal Sepsis; Sepsis; Infection
Sites: Karachi, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5
- hyperglycaemia2
- ammonia decreased1
- anion gap increased1
- blood lactic acid increased1
- brain oedema1
- cerebral infarction1
- drug ineffective for unapproved indication1
- maternal exposure during pregnancy1
- mycoplasma test positive1
- off label use1
- therapy non-responder1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Failure of scabies treatment: a systematic review and meta-analysis.
Mbuagbaw L, Sadeghirad B, Morgan RL, et al. · Br J Dermatol 2024 · Meta-Analysis, Systematic Review
- Scabies.
Johnstone PP, Strong M · BMJ Clin Evid 2008 · Systematic Review
- YCANTHTM (Cantharidin) Topical Solution.
Gupta AK, Mann A, Vincent K, et al. · Skinmed 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial.
McCann D, Barrett A, Cooper A, et al. · Lancet 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A systematic review on natural products with antimicrobial potential against WHO's priority pathogens.
SeyedAlinaghi S, Mehraeen E, Mirzapour P, et al. · Eur J Med Res 2025 · Systematic Review
- A Systems Vaccinology Approach Reveals the Mechanisms of Immunogenic Responses to Hantavax Vaccination in Humans.
Khan A, Shin OS, Na J, et al. · Sci Rep 2019 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Maia Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.